Evaluation of Resistance to Ciprofloxacin and Identification of Mutations in Topoisomerase Genes in Escherichia coli and Klebsiella pneumonia Isolated from Pediatric Urinary Tract Infections

Ghadiri, Keyghobad; Akya, Alisha; Elahi, Azam; Jafari, Somaye; Chegenelorestani, Roya

doi:10.4274/jpr.galenos.2019.16362

Cited by 5 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This observation had been investigated in the present study, and it was found that ESBL producing K. pneumoniae isolates had lower MIC values for ciprofloxacin than ESBL producing E. coli isolates (1-8 µg/ ml). Unusual mutations in multiple antibiotic resistance (mar) locus or alteration in outer-membrane protein in ESBL-producing E. coli strains are potential explanations for the observed higher MIC value for ciprofloxacin [15,16]. The results of the present study were following those reported by Panacek et al from Czech Republic [11].…”

Section: Discussionsupporting

confidence: 88%

Combination of silver nanoparticles with ineffective antibiotics against extended spectrum beta-lactamases producing isolates at Alexandria Main University Hospital, Egypt

Mohammed

Mourad

Alsewy

et al. 2021

Beni-Suef Univ J Basic Appl Sci

View full text Add to dashboard Cite

Background The context and purpose of the study: The spready dissemination of resistance mechanisms among extended spectrum beta-lactamases (ESBL) producing bacterial isolates has increasingly been reported. There is an urgent need to explore the antibacterial property of nontoxic biosafe compounds. This In-vitro experimental study aimed to evaluate the effect of silver nanoparticles (AgNPs) alone and in combination with ineffective antibiotics against ESBL producing isolates. Results Ciprofloxacin with AgNPs combination had the highest synergistic percentage against 91.43% of ESBL Escherichia coli isolates, and it was additive against 8.57% of them. As regards ESBL K. pneumoniae isolates, AgNPs with cefotaxime were synergistic against 75.00% of them, followed by ceftazidime and ciprofloxacin (62.50%). The least effective combination was ampicillin with AgNPs. The greatest enhancement of activity of the antibiotics was observed at silver minimum inhibitory concentration (MICAg) MICAg/2 and MICAg/4. At lower AgNPs concentrations, enhanced effects were less obvious. AgNPs inhibited the production of beta-lactamase enzymes in 91.43% of E. coli and 75% of Klebsiella pneumoniae isolates. Conclusion AgNPs are a valuable alternative to combat drug resistance, as they had synergistic effects when combined with different ineffective antibiotics against ESBL producing bacteria. AgNPs had lowered MIC values of antibiotics by several folds. Moreover, they inhibited the production of beta-lactamase enzymes.

show abstract

Section: Discussionsupporting

confidence: 88%

Combination of silver nanoparticles with ineffective antibiotics against extended spectrum beta-lactamases producing isolates at Alexandria Main University Hospital, Egypt

Mohammed

Mourad

Alsewy

et al. 2021

Beni-Suef Univ J Basic Appl Sci

View full text Add to dashboard Cite

show abstract

“…This might be because UTI occur more than in other systems seeking investigation and follow-up. Most isolates of clinical specimens in this study were from female patients, which is identical to these studies (Ghadiri et al, 2019;Mohammed et al, 2019;Naqid et al, 2020;Abd Al-Hamed and Abd Al-Mayah, 2021). The reason is back to the female lower urinary tract anatomy and its proximity to the reproductive organs (Czajkowski et al, 2021).…”

Section: G Phenotypic Detection Of Extended-spectrum β-Lactamase Prod...supporting

confidence: 85%

Bacteriological Characterization of Fluoroquinolones-Resistant Klebsiella pneumoniae Clinical Isolates During Covid-19 Pandemic

Masood

Yassin

2022

JLBSR

View full text Add to dashboard Cite

The treatment of Klebsiella pneumoniae infections has become more difcult due to the emergence of multidrug-resistant strains. Fluoroquinolones have been widely used to treat respiratory tract infections and urinary tract infections caused by different bacteria. Therefore, this study aimed to evaluate fluoroquinolones resistance and detect ESBL producers in various clinical samples in Duhok Province, Iraq. K. pneumoniae was identied from different clinical samples by conventional microbiological tests. In addition, antibiotic susceptibility was detected by the KirbyBauer disc diffusion method. Out of 120 K. pneumoniae isolates, 73.3% were causing urinary tract infections, in most cases, 74.2% were among females and 25.8% among males, and among those 120 isolates, 76.7% of isolates were from outpatients, and 23.3% were inpatients. The resistance rate among all samples was 52.5%, 36.7%, 33.3%, 33.3%, ciprofloxacin, levofloxacin, norfloxacin, and ofloxacin, respectively in urine samples, the resistance to nalidixic acid was 22.5%. Among 120 samples, only 12 isolates were hypermucoviscosity. About 25% of ciprofloxacin and 17.5% of levofloxacin resistances were ESBL producers simultaneously. According to this study, K. pneumoniae is more susceptible to norfloxacin, ofloxacin, and nalidixic acid than ciprofloxacin and levofloxacin. Additionally, this study establishes a link between ESBL and fluoroquinolone resistance.

show abstract

“…In a study conducted between 2016 and 2017, overall 15.3% samples of Klebsiella pneumonia and Escherichia coli showed resistance to ciprofloxacin. 15 …”

Section: Introductionmentioning

confidence: 99%

“…The clinical effectiveness of ciprofloxacin is affected due to the emergence of resistance in Gram-positive and Gram-negative bacteria. In a study conducted between 2016 and 2017, overall 15.3% samples of Klebsiella pneumonia and Escherichia coli showed resistance to ciprofloxacin …”

Section: Introductionmentioning

confidence: 99%

“…In a study conducted between 2016 and 2017, overall 15.3% samples of Klebsiella pneumonia and Escherichia coli showed resistance to ciprofloxacin. 15 Despite the approval of many fluoroquinolones, there has been a persistent effort to discover new quinolones to overcome the emergence of bacterial resistance. 16 As the development of a pioneer drug is uncertain since its therapeutic use is not clinically validated, 17 analogues of ciprofloxacin were generated to overrule a significant uncertainty from the overall risk of success.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Discovery of Novel Inhibitors of Bacterial DNA Gyrase Using a QSAR-Based Approach

et al. 2022

View full text Add to dashboard Cite

Type II topoisomerases like DNA gyrase initiate ATP-dependent negative supercoils in bacterial DNA. It is critical in all of the bacteria but is missing from eukaryotes, making it a striking target for antibacterials. Ciprofloxacin is a clinically approved drug, but its clinical effectiveness is affected by the emergence of resistance in both Gram-positive and Gram-negative bacteria. Thus, it is vital to identify novel compounds that can efficiently inhibit DNA gyrase, and quantitative structure–activity relationship (QSAR) modeling is a quick and economical means to do so. A QSAR-based virtual screening approach was applied to identify new gyrase inhibitors using an in-house -generated combinatorial library of 29828 compounds from seven ciprofloxacin scaffold structures. QSAR was built using a data set of 271 compounds, which were identified as positive and negative inhibitors from existing data reported in in vitro studies. The best QSAR model was developed using the 5-fold cross-validation Neural Network in Orange, and it was based on five PaDEL descriptors with an accuracy and sensitivity of 83%. As a result of screening of an in-house -built combinatorial library with the best-developed QSAR model, 675 compounds were identified as potential inhibitors of DNA gyrase. These inhibitors were further docked with DNA gyrase using AutoDock to compare the binding mode and score of the selected/screened compounds, and 615 compounds exhibited a docking score comparable to or lower than that of ciprofloxacin. Out of these, the top five analogues 902b, 9699f, 4419f, 5538f, and 898b reported in our study have binding scores of −13.81, −12.95, −12.52, −12.43, and −12.41 kcal/mol, respectively. The MD simulations of these five analogues for 100 ns supported the interaction stability of analogues with Escherichia coli DNA gyrase. Ninety-one per cent of the analogues screened by the QSAR model displayed better binding energy than ciprofloxacin, demonstrating the efficacy of the generated model. The NN-QSAR model proposed in this manuscript can be downloaded from .

show abstract

Evaluation of Resistance to Ciprofloxacin and Identification of Mutations in Topoisomerase Genes in Escherichia coli and Klebsiella pneumonia Isolated from Pediatric Urinary Tract Infections

Cited by 5 publications

References 15 publications

Combination of silver nanoparticles with ineffective antibiotics against extended spectrum beta-lactamases producing isolates at Alexandria Main University Hospital, Egypt

Combination of silver nanoparticles with ineffective antibiotics against extended spectrum beta-lactamases producing isolates at Alexandria Main University Hospital, Egypt

Bacteriological Characterization of Fluoroquinolones-Resistant Klebsiella pneumoniae Clinical Isolates During Covid-19 Pandemic

Discovery of Novel Inhibitors of Bacterial DNA Gyrase Using a QSAR-Based Approach

Contact Info

Product

Resources

About